TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14871462

Group type: EXPERIMENTAL
Intervention: 1 g oral moist snuff
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11495073

Group type: EXPERIMENTAL
Intervention: Psychological intervention (PI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Routine surgical care (RC)
Number of subjects: 42
Study: 9137797

Group type: EXPERIMENTAL
Intervention: CMF treatment in TP-positive tumours
Number of subjects: 328

Group type: COMPARATOR
Intervention: Non-treated patients with TP-positive tumours
Number of subjects: 328
Study: 7547544

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 0
Study: 2908103

Group type: EXPERIMENTAL
Intervention: Human calcitonin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study: 30755119

Group type: EXPERIMENTAL
Intervention: Prevention Nail System (PNS)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 72
Study: 27872156

Group type: EXPERIMENTAL
Intervention: Systolic BP <120 mmHg
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Diastolic BP <70 mmHg
Number of subjects: 1441
Study: 25523190

Group type: EXPERIMENTAL
Intervention: Daily vitamin D therapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Stoss vitamin D therapy
Number of subjects: 73
Study: 23318104

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba dry extract
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: α‐lipoic acid plus vitamin C
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Papaverine chlorhydrate plus vitamin E
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 20589925

Group type: EXPERIMENTAL
Intervention: S. officinalis aroma
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: S. lavandulaefolia aroma
Number of subjects: 135

Group type: COMPARATOR
Intervention: No aroma (control)
Number of subjects: 135
Study: 18816361

Group type: EXPERIMENTAL
Intervention: Intervention DVD featuring a White female communicator
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control DVD featuring 2 Black female communicators
Number of subjects: 167
Study: 17285994

Group type: EXPERIMENTAL
Intervention: HA-Bone cement used to repair palate tabular damage
Number of subjects: 40
Study: 12888639

Group type: EXPERIMENTAL
Intervention: Diurnal tube feeding (12-h schedule)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nocturnal tube feeding (12-h schedule)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 24-h tube feeding
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo feeding (<0.4 MJ/d)
Number of subjects: 6
Study: 11138755

Group type: EXPERIMENTAL
Intervention: Manipulations of the distinctness construct
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-mutability as a contextual variable
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social comparisons on self-evaluative judgments and behavioral predictions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mood measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Importance ratings of the focal comparison dimension
Number of subjects: 0
Study: 9174681

Group type: EXPERIMENTAL
Intervention: 800 mg esuprone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 300 mg moclobemide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1415368

Group type: EXPERIMENTAL
Intervention: Epoetin-alpha (Cilag)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epoetin-beta (Boehringer)
Number of subjects: 50
Study: 6367452

Group type: EXPERIMENTAL
Intervention: Intravenous cimetidine (300 mg every six hours)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Cimetidine tablets (300 mg three times a day and at bedtime)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Hourly antacids (Mylanta II liquid 30 ml every hour)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Cimetidine plus hourly antacids
Number of subjects: 479

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 479
Study: 30811630

Group type: EXPERIMENTAL
Intervention: Topical application of 2g of nanorap formulation (50mg lidocaine + 50mg prilocaine)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (control formulation)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nanorap formulation
Number of subjects: 120
Study: 29599348

Group type: EXPERIMENTAL
Intervention: Pemetrexed and carboplatin (PC)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Gemcitabine and carboplatin (GC)
Number of subjects: 222
Study: 27077267

Group type: EXPERIMENTAL
Intervention: Single-needle arthrocentesis (Shepard cannula)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Double-needle arthrocentesis
Number of subjects: 56
Study: 25631504

Group type: EXPERIMENTAL
Intervention: Metronidazole sustained-release film combined with minocycline hydrochloride
Number of subjects: 138

Group type: COMPARATOR
Intervention: Minocycline hydrochloride
Number of subjects: 138
Study: 22775467

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 820 nm; continuous wave; output power: 50 mW; exposure duration: 5 sec; energy dose: 0.25 J; energy density: 7.96 J/cm(2) for each shot
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo control (no laser treatment)
Number of subjects: 19
Study: 19879750

Group type: EXPERIMENTAL
Intervention: E120 (epirubicin 120 mg/m²)
Number of subjects: 411

Group type: COMPARATOR
Intervention: EC-CMF (epirubicin 90 mg/m² plus cyclophosphamide 600 mg/m² followed by CMF)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: E120
Number of subjects: 411

Group type: COMPARATOR
Intervention: EC-CMF
Number of subjects: 411
Study: 18517036

Group type: EXPERIMENTAL
Intervention: Gaboxadol (GBX) 15 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 16029679

Group type: EXPERIMENTAL
Intervention: 5% niacinamide applied twice daily for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vehicle control applied twice daily for 12 weeks
Number of subjects: 50
Study: 11812810

Group type: EXPERIMENTAL
Intervention: Telephone reminder intervention
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (no telephone reminder)
Number of subjects: 143
Study: 10412676

Group type: EXPERIMENTAL
Intervention: Cluster schedule
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Conventional schedule
Number of subjects: 63

Group type: COMPARATOR
Intervention: No immunotherapy
Number of subjects: 63
Study: 7598088

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (Stomach, Hunger, Shen Men points) with diet and exercise program
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (Stomach, Hunger points)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Low calorie diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo ear points stimulation
Number of subjects: 19
Study: 1805138

Group type: EXPERIMENTAL
Intervention: Cefadroxil
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amoxicillin with clavulanic acid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid combination
Number of subjects: 6
Study: 6339961

Group type: EXPERIMENTAL
Intervention: Regimen A (intensive courses of methotrexate with vincristine and prednisone reinductions and administration of cyclophosphamide)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Regimen B (courses of methotrexate alternated with courses of 6‐mercaptopurine during consolidation and intensification therapy)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Protocol 0276/A (similar to regimen B but with L‐asparaginase and prolonged therapy duration)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 88

Group type: COMPARATOR
Intervention: Combination of methotrexate and 6‐mercaptopurine
Number of subjects: 88
Study: 31462863

Group type: EXPERIMENTAL
Intervention: Variolink N (Group VN)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Multilink N (Group MN)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Multilink Speed (Group MS)
Number of subjects: 45
Study: 30390895

Group type: EXPERIMENTAL
Intervention: 1 g/day of EPA‐enriched oral nutrition supplementation (ONS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: EPA‐free ONS of similar energy (control group)
Number of subjects: 50
Study: 26811060

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask (LM)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Endotracheal Intubation (ETI)
Number of subjects: 68
Study: 24534289

Group type: EXPERIMENTAL
Intervention: B‐Lynch suture
Number of subjects: 43
Study: 22971879

Group type: EXPERIMENTAL
Intervention: Standing desk
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sitting desk
Number of subjects: 20
Study: 20408345

Group type: EXPERIMENTAL
Intervention: sublingual latex extract
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 17223657

Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF) 20 mg once daily for 24 weeks
Number of subjects: 15
Study: 17078441

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (penetrating needling, scalp acupuncture, strong/electric needling on body points)
Number of subjects: 98
Study: 15220599

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement (InflammEnz, Enzymes, Inc., Parkville, Mo.) - four capsules per day for 7 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 10910797

Group type: EXPERIMENTAL
Intervention: Cognitive adaptation training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard medication follow-up plus a condition designed to control for therapist time and provide environmental changes unrelated to cognitive deficits
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard medication follow-up only
Number of subjects: 45
Study: 8835112

Group type: EXPERIMENTAL
Intervention: ZVD (500 mg daily) + rG‐CSF (10 micrograms/Kg/biweekly) + Epo (50 IU/Kg/biweekly)
Number of subjects: 20

Group type: COMPARATOR
Intervention: ZVD (500 mg/day) alone
Number of subjects: 20
Study: 1279214

Group type: EXPERIMENTAL
Intervention: 2 mg terazosin
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: 5 mg terazosin
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: 10 mg terazosin
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 3901170

Group type: EXPERIMENTAL
Intervention: Atenolol (200 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Diltiazem (240 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30778710

Group type: EXPERIMENTAL
Intervention: Tongue cleaning intervention
Number of subjects: 95

Group type: COMPARATOR
Intervention: No tongue cleaning intervention (Control)
Number of subjects: 95
Study: 28731003

Group type: EXPERIMENTAL
Intervention: Arm A: Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 intravenously every 3 weeks for three cycles followed by Pemetrexed consolidation every 3 weeks for 4 cycles.
Number of subjects: 598

Group type: COMPARATOR
Intervention: Arm B: Standard therapy with Etoposide 50 mg/m2 and Cisplatin 50 mg/m2 intravenously every 4 weeks for two cycles followed by two cycles of consolidation platinum-based doublet chemotherapy.
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Arm A: Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 intravenously.
Number of subjects: 598

Group type: COMPARATOR
Intervention: Arm B: Standard therapy with Etoposide and Cisplatin.
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Arm A: Pemetrexed and Cisplatin.
Number of subjects: 598

Group type: COMPARATOR
Intervention: Arm B: Etoposide and Cisplatin.
Number of subjects: 598
Study: 25111959

Group type: EXPERIMENTAL
Intervention: Bendamustine 120 mg/m2
Number of subjects: 16
Study: 23597114

Group type: EXPERIMENTAL
Intervention: DePuy ASR Hip Resurfacing System (RHA)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cobalt ions
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Chromium ions
Number of subjects: 38
Study: 21567350

Group type: EXPERIMENTAL
Intervention: High Aerobic Endurance Group (HEG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low Aerobic Endurance Group (LEG)
Number of subjects: 30
Study: 18489687

Group type: EXPERIMENTAL
Intervention: Structured educational intervention programme with two visits to a nurse specialized in COPD care.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard care (Control group).
Number of subjects: 52
Study: 16645967

Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate 7.5 mg/week + cyclosporine 2.5 mg/kg/day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Monotherapy (methotrexate + placebo-cyclosporine)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate + intraarticular glucocorticoid)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate + cyclosporine)
Number of subjects: 160
Study: 14521003

Group type: EXPERIMENTAL
Intervention: Video intervention (generic and individualized videos)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 82
Study: 11200920

Group type: EXPERIMENTAL
Intervention: Behavioural intervention (15 individual sessions including counseling, relaxation, diabetes education, and cognitive strategies)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study: 8983088

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 4 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cortisol (CORT) 10 mg/h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1457111

Group type: EXPERIMENTAL
Intervention: Desflurane (1.25 MAC for 15 minutes)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isoflurane (1.6%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atracurium (0.05, 0.1, or 0.15 mg/kg IV) with desflurane
Number of subjects: 50

Group type: COMPARATOR
Intervention: Atracurium (0.05, 0.1, or 0.15 mg/kg IV) with isoflurane
Number of subjects: 50
Study: 6091501

Group type: EXPERIMENTAL
Intervention: Metoclopramide, 10 mg in the morning (Group II)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg (Group III)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg and metoclopramide, 10 mg in the morning (Group IV)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg at bedtime and in the morning (Group V)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg at bedtime and in the morning and metoclopramide, 10 mg in the morning (Group VI)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ranitidine, 300 mg in the morning (Group VII)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ranitidine, 300 mg and metoclopramide, 10 mg in the morning (Group VIII)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ranitidine, 300 mg at bedtime and in the morning (Group IX)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ranitidine, 300 mg at bedtime and in the morning and metoclopramide, 10 mg in the morning (Group X)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 150
Study: 30406847

Group type: EXPERIMENTAL
Intervention: Dual-focus endoscopy with narrow-band imaging (DF-NBI)
Number of subjects: 170

Group type: COMPARATOR
Intervention: White light imaging (WLI)
Number of subjects: 170
Study: 30055926

Group type: EXPERIMENTAL
Intervention: 50% SCAM inclusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 100% SCAM inclusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0% SCAM inclusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: SCAM diets
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: SCAM inclusion
Number of subjects: 6
Study: 27267500

Group type: EXPERIMENTAL
Intervention: Enhanced cognitive behavioral therapy (CBT‐E)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Focal psychodynamic therapy (FPT)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Optimized treatment as usual (TAU‐O)
Number of subjects: 242
Study: 25127703

Group type: EXPERIMENTAL
Intervention: Cationic emulsion (CE) - Cationorm
Number of subjects: 79

Group type: COMPARATOR
Intervention: PVA-P - Refresh
Number of subjects: 79
Study: 22581822

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 148

Group type: COMPARATOR
Intervention: Carboplatin plus paclitaxel
Number of subjects: 148
Study: 19502285

Group type: EXPERIMENTAL
Intervention: Oxytocin 5 u (first dose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oxytocin 5 u (second dose)
Number of subjects: 20
Study: 17718902

Group type: EXPERIMENTAL
Intervention: Students informed about the benefits of changing answers; Outcome: changed answers significantly more often than those not informed.
Number of subjects: 79

Group type: COMPARATOR
Intervention: Students not informed about the benefits of changing answers; Outcome: changed answers less often than those informed.
Number of subjects: 79
Study: 15172774

Group type: EXPERIMENTAL
Intervention: amphotericin B plus flucytosine (100 mg/kg daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: amphotericin B (0.7 mg/kg daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: amphotericin B plus fluconazole (400 mg daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: triple therapy with amphotericin B, flucytosine, and fluconazole
Number of subjects: 64
Study: 11368133

Group type: EXPERIMENTAL
Intervention: Video information prior to attendance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Written information (implied control)
Number of subjects: 0
Study: 9083228

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 21

Group type: COMPARATOR
Intervention: NaCl (saline)
Number of subjects: 21
Study: 8259900

Group type: EXPERIMENTAL
Intervention: Quantitative progressive exercise muscle rehabilitation program (QPE) added to physical therapy (PT) program
Number of subjects: 40
Study: 3554290

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 30938078

Group type: EXPERIMENTAL
Intervention: Personal control dimension of illness representation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Timeline cyclical dimension of illness representation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Severity of depression
Number of subjects: 70
Study: 29084330

Group type: EXPERIMENTAL
Intervention: Microperimetry
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Survival analysis
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Macular sensitivity
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intereye symmetry for microperimetry sensitivity
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Foveal sensitivity
Number of subjects: 56
Study: 25802473

Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 23862715

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 9.5% hydrogen peroxide
Number of subjects: 96
Study: 21956168

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily for 3 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18684743

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every other week for up to 120 weeks
Number of subjects: 245
Study: 17250578

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine dentifrice gel (CHX‐DGel, Perio.Aid)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Regular dentifrice (RegD, Everclean HEMA)
Number of subjects: 96

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine mouthwash (CHX‐MW, Perio.Aid)
Number of subjects: 96
Study: 15710852

Group type: EXPERIMENTAL
Intervention: Rasagiline 1.0 mg/d
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Rasagiline 0.5 mg/d
Number of subjects: 472

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Rasagiline 1.0 mg/d vs Placebo
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Rasagiline 0.5 mg/d vs Placebo
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Rasagiline (both dosages)
Number of subjects: 472
Study: 12043767

Group type: EXPERIMENTAL
Intervention: Anabolic steroids, vitamin D and calcium
Number of subjects: 63

Group type: COMPARATOR
Intervention: Calcium only (Control)
Number of subjects: 63
Study: 10612342

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 177
Study: 7861490

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg, orally 3 times a day for 4 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Allopurinol (0.2 gm, orally 3 times a day for 4 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nifedipine plus Allopurinol
Number of subjects: 40

Group type: COMPARATOR
Intervention: No medication (Control group)
Number of subjects: 40
Study: 2024742

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Thiopentone plus Alfentanil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol plus Alfentanil
Number of subjects: 40
Study: 6791203

Group type: EXPERIMENTAL
Intervention: Lentizol (sustained-release amitriptyline)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ordinary amitriptyline tablets
Number of subjects: 6
Study: 31698014

Group type: EXPERIMENTAL
Intervention: 25% intraoral sucrose
Number of subjects: 271

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 271
Study: 30670228

Group type: EXPERIMENTAL
Intervention: Dual-task aquatic exercise program, twice a week for 10 weeks, 40 minutes per session in a heated pool (33°C)
Number of subjects: 28
Study: 28713116

Group type: EXPERIMENTAL
Intervention: LASER therapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Combination of exercise and LASER therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 46